Dallas, TX (PRWEB) January 01, 2015 -- The report "Retinopathy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Retinopathy. Retinopathy is due to unrelenting or acute damage to the retina of the eye. Retinopathy is often a sign of another medical condition and the most common causes are diabetes and hypertension. Treatment is based on the cause of the retinopathy and may include laser therapy to the retina.
It also reviews key players involved in the therapeutic development for Retinopathy and special features on late-stage and discontinued projects. Companies discussed in this Retinopathy Pipeline Review H2 2014 report include Avalanche Biotechnologies, Inc., Biomar Microbial Technologies, GTx, Inc., Navigen Pharmaceuticals, Inc., SIFI S.p.A. Complete Report is Available @ http://www.reportsnreports.com/reports/321899-retinopathy-pipeline-review-h2-2014.html .
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy - Overview 7
Pipeline Products for Retinopathy - Comparative Analysis 8
Retinopathy - Therapeutics under Development by Companies 9
Retinopathy - Therapeutics under Investigation by Universities/Institutes 10
Retinopathy - Pipeline Products Glance 11
Early Stage Products 11
Unknown Stage Products 12
Retinopathy - Products under Development by Companies 13
Retinopathy - Products under Investigation by Universities/Institutes 14
Retinopathy - Companies Involved in Therapeutics Development 15
Avalanche Biotechnologies, Inc. 15
Biomar Microbial Technologies 16
GTx, Inc. 17
Navigen Pharmaceuticals, Inc. 18
SIFI S.p.A 19
Retinopathy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 25
AVA-311 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Beta-LGND2 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IB-12A157 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NAV-2729 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Recombinant Protein for Oncology and Ophthalmology - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SF-106 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SF-113 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit Arf6 for Multiple Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Retinopathy - Dormant Projects 36
Retinopathy - Discontinued Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=321899 .
List of Tables
Number of Products under Development for Retinopathy, H2 2014 7
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Retinopathy - Pipeline by Avalanche Biotechnologies, Inc., H2 2014 15
Retinopathy - Pipeline by Biomar Microbial Technologies, H2 2014 16
Retinopathy - Pipeline by GTx, Inc., H2 2014 17
Retinopathy - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 18
Retinopathy - Pipeline by SIFI S.p.A, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 24
Retinopathy - Dormant Projects, H2 2014 36
Retinopathy - Discontinued Products, H2 2014 37
List of Figures
Number of Products under Development for Retinopathy, H2 2014 7
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Molecule Types, H2 2014 24
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, ReportsnReports, http://www.marketreportsonline.com/, +1 (888) 391-5441, [email protected]
Share this article